Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Vidhula Ahire

Postdoctoral Researcher Associate in Metastasis Metabolism

Vidhula Ahire obtained her PhD in Biotechnology from Savitribai Phule Pune University and BARC, India focusing on radiosensitization in cervical cancer. She was awarded the Australian Endeavour Research Fellowship to study breast cancer biomarkers at Deakin University. She has worked exclusively in radiobiology labs across leading institutes, including AMC (Netherlands) on hyperthermia-induced synthetic lethality, GANIL (France) on radiation effects in 3D bioprinting models, Anticancer Biosciences (China) on synthetic lethality projects, and Institut Curie (France) on proton mini-beam therapy for glioblastoma. Currently, she is a Postdoctoral Research Associate at the University of Oxford (Radiobiology research Institute), focusing on radionuclide therapies for prostate cancer. She has extensive teaching experience and is an active member of several international scientific societies. Her work has earned multiple awards, including from ESSR, NIH/NIAID, and FABA. Her global research journey reflects a strong commitment to radiobiology innovation and international collaboration.